KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) EBIT Margin (2019 - 2025)

Royalty Pharma's EBIT Margin history spans 7 years, with the latest figure at 62.44% for Q4 2025.

  • For Q4 2025, EBIT Margin rose 154.0% year-over-year to 62.44%; the TTM value through Dec 2025 reached 65.58%, up 848.0%, while the annual FY2025 figure was 65.58%, 848.0% up from the prior year.
  • EBIT Margin for Q4 2025 was 62.44% at Royalty Pharma, down from 70.11% in the prior quarter.
  • Across five years, EBIT Margin topped out at 134.23% in Q2 2021 and bottomed at 85.31% in Q4 2022.
  • The 5-year median for EBIT Margin is 50.96% (2021), against an average of 52.44%.
  • The largest annual shift saw EBIT Margin crashed -11196bps in 2022 before it skyrocketed 18814bps in 2023.
  • A 5-year view of EBIT Margin shows it stood at 26.65% in 2021, then crashed by -420bps to 85.31% in 2022, then soared by 221bps to 102.82% in 2023, then crashed by -41bps to 60.9% in 2024, then rose by 3bps to 62.44% in 2025.
  • Per Business Quant, the three most recent readings for RPRX's EBIT Margin are 62.44% (Q4 2025), 70.11% (Q3 2025), and 36.26% (Q2 2025).